Pembrolizumab
- Generic Name
- Pembrolizumab
- Brand Names
- Keytruda
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1374853-91-4
- Unique Ingredient Identifier
- DPT0O3T46P
- Background
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...
- Indication
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
- Associated Conditions
- Advanced Endometrial Cancer, Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Cervical Cancer, Metastatic Esophageal Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Triple Negative Breast Cancers, Metastatic Urothelial Carcinoma (UC), Metastatic cutaneous squamous cell carcinoma, Metastic Renal Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage II, Persistent Cervical Cancer, Recurrent Cervical Cancer, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Renal Cell Carcinoma (RCC), Resectable Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Stage III Melanoma, Stage IIIA Non Small Cell Lung Cancer, Unresectable Melanoma, Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma, High risk, early Triple Negative Breast Cancer, High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG, Locally advanced Adenocarcinomas of the Gastroesophageal Junction, Locally advanced Esophageal Carcinoma, Locally advanced Urothelial Carcinoma, Metastatic HER2-positive Adenocarcinoma of the Stomach, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic High Tumor Mutation Burden Solid Tumors, Metastatic Merkel Cell Carcinoma (MCC), Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic Mismatch repair deficient (dMMR) solid tumors, Recurrent Cutaneous Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction, Recurrent, locally advanced Merkel Cell Carcinoma, Refractory Classical Hodgkin's Lymphoma, Relapsed Classical Hodgkin's Lymphoma, Stage 3 Non-Small Cell Lung Carcinoma (NSCLC), Unresectable High Tumor Mutation Burden Solid Tumors, Unresectable Microsatellite Instability High Colorectal Cancer, Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors, Unresectable Mismatch Repair Deficient Colorectal Cancer, Unresectable Mismatch repair deficient (dMMR) solid tumors, Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach, Unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Unresectable, locally recurrent Triple Negative Breast Cancer, Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-05-07
- Target Recruit Count
- 3
- Registration Number
- NCT06378047
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT06377566
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
CARE1 Pragmatic Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1250
- Registration Number
- NCT06364631
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 76
- Registration Number
- NCT06366347
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 24
- Registration Number
- NCT06364917
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
PSMA Therapy and Immunotherapy in Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 37
- Registration Number
- NCT06361810
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT06356155
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 675
- Registration Number
- NCT06357533
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT06353906
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Noord-Holland, Netherlands
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 12
- Registration Number
- NCT06353997
- Locations
- 🇺🇸
Ellison Institute of Technology (EITM), Los Angeles, California, United States
🇺🇸Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
🇺🇸Providence St. Vincent Medical Center, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.